{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:25:01Z","timestamp":1790364301167,"version":"4.1.0"},"reference-count":67,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019460","name":"Weill Cornell Medicine - Qatar","doi-asserted-by":"publisher","award":["Biomedical Research Program"],"award-info":[{"award-number":["Biomedical Research Program"]}],"id":[{"id":"10.13039\/100019460","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar Genome Programme, and Qatar University Biomedical Research Center","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,3,14]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SARS-CoV-2 infection is associated with protection against reinfection. This study analysed this protection across different reinfection symptoms and severities, comparing the preomicron and omicron eras.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nationwide, matched, test-negative, case\u2013control study was conducted in Qatar from 5 February 2020 to 12 March 2024. The preomicron analysis used a sample of 509\u2009949 positive and 8\u2009494\u2009782 negative tests, while the omicron analysis included 682\u2009257 positive and 6\u2009904\u2009044 negative tests. Data were sourced from Qatar\u2019s national databases for COVID-19 laboratory testing, vaccination, hospitalisation and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Effectiveness of preomicron infection against preomicron reinfection was estimated at 80.9% (95% CI: 79.1% to 82.6%) for asymptomatic reinfection, 87.5% (95% CI: 86.1% to 88.9%) for symptomatic reinfection, 97.8% (95% CI: 95.7% to 98.9%) for severe COVID-19 reinfection, 100.0% (95% CI: 97.5% to 100.0%) for critical COVID-19 reinfection and 88.1% (95% CI: 50.3% to 97.2%) for fatal COVID-19 reinfection. For omicron infection against omicron reinfection, the estimates were 46.4% (95% CI: 36.9% to 54.4%) for asymptomatic reinfection, 52.8% (95% CI: 44.4% to 60.0%) for symptomatic reinfection, 100.0% (95% CI: 55.4% to 100.0%) for severe COVID-19 reinfection, 100.0% (95% CI: 15.1% to 100.0%) for critical COVID-19 reinfection, and 75.2% (95% CI: \u221258.8% to 97.5%) for fatal COVID-19 reinfection. Effectiveness over time since previous infection showed no discernible decline in protection against all forms of reinfection in the preomicron era, but a rapid decline against asymptomatic and symptomatic reinfections in the omicron era.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A gradient of protection against reinfection is evident, with the highest protection observed against severe forms of COVID-19. Over time, this gradient becomes more pronounced, as protection against asymptomatic and symptomatic reinfections decreases, while protection against severe outcomes remains strong.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002718","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T19:44:52Z","timestamp":1743018292000},"page":"e002718","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-9688","authenticated-orcid":false,"given":"Layan","family":"Sukik","sequence":"first","affiliation":[{"name":"Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar"},{"name":"World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV\/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine\u2013Qatar, Cornell University, Qatar Foundation \u2013 Education City, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-6968","authenticated-orcid":false,"given":"Hiam","family":"Chemaitelly","sequence":"additional","affiliation":[{"name":"Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar"},{"name":"World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV\/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine\u2013Qatar, Cornell University, Qatar Foundation \u2013 Education City, Doha, Qatar"},{"name":"Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssein H","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Coyle","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar"},{"name":"Hamad Medical Corporation, Doha, Qatar"},{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sidra Medicine, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad R","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi M","family":"Yassine","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar"},{"name":"Biomedical Research Center, QU Health, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa A","family":"Al Thani","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar"},{"name":"Biomedical Research Center, QU Health, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina","family":"Al-Kanaani","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einas","family":"Al-Kuwari","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jeremijenko","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvar Hassan","family":"Kaleeckal","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Nizar","family":"Latif","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyazuddin Mohammad","family":"Shaik","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan F","family":"Abdul-Rahim","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheyath K","family":"Nasrallah","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar"},{"name":"Biomedical Research Center, QU Health, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ghaith","family":"Al-Kuwari","sequence":"additional","affiliation":[{"name":"Primary Health Care Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Butt","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA"},{"name":"Hamad Medical Corporation, Doha, Qatar"},{"name":"Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad Eid","family":"Al-Romaihi","sequence":"additional","affiliation":[{"name":"Ministry of Public Health, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H","family":"Al-Thani","sequence":"additional","affiliation":[{"name":"Ministry of Public Health, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullatif","family":"Al-Khal","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bertollini","sequence":"additional","affiliation":[{"name":"Ministry of Public Health, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-0506","authenticated-orcid":false,"given":"Laith J","family":"Abu-Raddad","sequence":"additional","affiliation":[{"name":"Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar"},{"name":"World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV\/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine\u2013Qatar, Cornell University, Qatar Foundation \u2013 Education City, Doha, Qatar"},{"name":"Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA"},{"name":"Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar"},{"name":"College of Health and Life Sciences, Hamad bin Khalifa University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025111320453027000_12.1.e002718.1","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac109","article-title":"Duration of immune protection of SARS-CoV-2 natural infection against reinfection","volume":"29","author":"Chemaitelly","year":"2022","journal-title":"J Travel Med"},{"key":"2025111320453027000_12.1.e002718.2","doi-asserted-by":"crossref","unstructured":"Chemaitelly H , Ayoub HH , Tang P , et al . Patterns in repeat reinfections: pre and post omicron emergence. Epidemiology [Preprint]. doi:10.1101\/2023.06.29.23292041","DOI":"10.1101\/2023.06.29.23292041"},{"key":"2025111320453027000_12.1.e002718.3","doi-asserted-by":"crossref","unstructured":"Chemaitelly H , Ayoub HH , Coyle P , et al . Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron. Nature New Biol 2025. doi:10.1038\/s41586-024-08511-9","DOI":"10.1038\/s41586-024-08511-9"},{"key":"2025111320453027000_12.1.e002718.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5793"},{"key":"2025111320453027000_12.1.e002718.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6522"},{"key":"2025111320453027000_12.1.e002718.6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature01509","article-title":"Ecological and immunological determinants of influenza evolution","volume":"422","author":"Ferguson","year":"2003","journal-title":"Nature New Biol"},{"key":"2025111320453027000_12.1.e002718.7","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890120103"},{"key":"2025111320453027000_12.1.e002718.8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz281"},{"key":"2025111320453027000_12.1.e002718.9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijid.2022.04.045","article-title":"Epidemiology of influenza virus reinfection in Guangxi, China: a retrospective analysis of a nine-year influenza surveillance data: Characteristics of influenza virus reinfection","volume":"120","author":"Wang","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2025111320453027000_12.1.e002718.10","doi-asserted-by":"crossref","first-page":"e1830","DOI":"10.1093\/cid\/ciaa1846","article-title":"Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting","volume":"73","author":"Abu-Raddad","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025111320453027000_12.1.e002718.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100861","article-title":"SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy","volume":"35","author":"Abu-Raddad","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025111320453027000_12.1.e002718.12","doi-asserted-by":"publisher","DOI":"10.1038\/2Fs41579-023-00878-2"},{"key":"2025111320453027000_12.1.e002718.13","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/s41564-023-01504-w","article-title":"SARS-CoV-2 evolution in the Omicron era","volume":"8","author":"Roemer","year":"2023","journal-title":"Nat Microbiol"},{"key":"2025111320453027000_12.1.e002718.14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41591-022-01836-w","article-title":"An early warning system for emerging SARS-CoV-2 variants","volume":"28","author":"Subissi","year":"2022","journal-title":"Nat Med"},{"key":"2025111320453027000_12.1.e002718.15","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2025111320453027000_12.1.e002718.16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJMc2200133","article-title":"Protection against the Omicron Variant from Previous SARS-CoV-2 Infection","volume":"386","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"2025111320453027000_12.1.e002718.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.08.026"},{"key":"2025111320453027000_12.1.e002718.18","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat Microbiol"},{"key":"2025111320453027000_12.1.e002718.19","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae053","article-title":"Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant","volume":"31","author":"Chemaitelly","year":"2024","journal-title":"J Travel Med"},{"key":"2025111320453027000_12.1.e002718.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2110300"},{"key":"2025111320453027000_12.1.e002718.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2209306"},{"key":"2025111320453027000_12.1.e002718.22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJMc2214114","article-title":"Protection against Reinfection with the Omicron BA.2.75 Subvariant","volume":"388","author":"Chemaitelly","year":"2023","journal-title":"N Engl J Med"},{"key":"2025111320453027000_12.1.e002718.23","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1016\/j.vaccine.2024.04.026","article-title":"Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient","volume":"42","author":"Sukik","year":"2024","journal-title":"Vaccine (Auckl)"},{"key":"2025111320453027000_12.1.e002718.24","unstructured":"World Health Organization (WHO) . Living guidance for clinical management of COVID-19. Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-2 [Accessed 27 Feb 2023]."},{"key":"2025111320453027000_12.1.e002718.25","unstructured":"World Health Organization (WHO) . International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available: https:\/\/www.who.int\/publications\/m\/item\/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death [Accessed 27 Feb 2023]."},{"key":"2025111320453027000_12.1.e002718.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-85428-7","article-title":"Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic","volume":"11","author":"Abu-Raddad","year":"2021","journal-title":"Sci Rep"},{"key":"2025111320453027000_12.1.e002718.27","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac107","article-title":"Resurgence of influenza A infections in children after the relaxation of COVID-19-related social distancing measures and normalization of international travel in Qatar","volume":"29","author":"P\u00e9rez-L\u00f3pez","year":"2022","journal-title":"J Travel Med"},{"key":"2025111320453027000_12.1.e002718.28","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ppul.24933","article-title":"Dramatic decrease of laboratory-confirmed influenza A after school closure in response to COVID-19","volume":"55","author":"Perez-Lopez","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2025111320453027000_12.1.e002718.29","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2025111320453027000_12.1.e002718.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2203965"},{"key":"2025111320453027000_12.1.e002718.31","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad106","article-title":"Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections","volume":"30","author":"Chemaitelly","year":"2023","journal-title":"J Travel Med"},{"key":"2025111320453027000_12.1.e002718.32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMc2117933","article-title":"Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"2025111320453027000_12.1.e002718.33","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"2025111320453027000_12.1.e002718.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.09.005"},{"key":"2025111320453027000_12.1.e002718.35","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(23)00058-0","article-title":"Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study","volume":"23","author":"Chemaitelly","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025111320453027000_12.1.e002718.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012291","article-title":"All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic","volume":"8","author":"AlNuaimi","year":"2023","journal-title":"BMJ Glob Health"},{"key":"2025111320453027000_12.1.e002718.37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/aje\/kwad239","article-title":"Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design","volume":"193","author":"Ayoub","year":"2024","journal-title":"Am J Epidemiol"},{"key":"2025111320453027000_12.1.e002718.38","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine (Auckl)"},{"key":"2025111320453027000_12.1.e002718.39","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.vaccine.2017.04.037","article-title":"Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls","volume":"35","author":"Verani","year":"2017","journal-title":"Vaccine (Auckl)"},{"key":"2025111320453027000_12.1.e002718.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2022.112911"},{"key":"2025111320453027000_12.1.e002718.41","doi-asserted-by":"publisher","DOI":"10.1177\/01632787211047932"},{"key":"2025111320453027000_12.1.e002718.42","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1363045","article-title":"Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation","volume":"11","author":"Chemaitelly","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2025111320453027000_12.1.e002718.43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjph-2023-000479","article-title":"Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar","volume":"1","author":"Chemaitelly","year":"2023","journal-title":"BMJ Public Health"},{"key":"2025111320453027000_12.1.e002718.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01446-y"},{"key":"2025111320453027000_12.1.e002718.45","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMc2119432","article-title":"Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"2025111320453027000_12.1.e002718.46","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab083","article-title":"Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses","volume":"28","author":"Abu-Raddad","year":"2021","journal-title":"J Travel Med"},{"key":"2025111320453027000_12.1.e002718.47","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.11.05005","article-title":"Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19","volume":"11","author":"Ayoub","year":"2021","journal-title":"J Glob Health"},{"key":"2025111320453027000_12.1.e002718.48","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102646","article-title":"SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals","volume":"24","author":"Coyle","year":"2021","journal-title":"iScience"},{"key":"2025111320453027000_12.1.e002718.49","doi-asserted-by":"publisher","DOI":"10.3201\/eid2705.204365"},{"key":"2025111320453027000_12.1.e002718.50","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab221","article-title":"SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar","volume":"8","author":"Al-Thani","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025111320453027000_12.1.e002718.51","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32363-4","article-title":"Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage","volume":"13","author":"Chemaitelly","year":"2022","journal-title":"Nat Commun"},{"key":"2025111320453027000_12.1.e002718.52","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"key":"2025111320453027000_12.1.e002718.53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-35815-7","article-title":"Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5","volume":"14","author":"Tseng","year":"2023","journal-title":"Nat Commun"},{"key":"2025111320453027000_12.1.e002718.54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104734","article-title":"Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study","volume":"95","author":"Altarawneh","year":"2023","journal-title":"EBioMedicine"},{"key":"2025111320453027000_12.1.e002718.55","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2103916"},{"key":"2025111320453027000_12.1.e002718.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2211314"},{"key":"2025111320453027000_12.1.e002718.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2025111320453027000_12.1.e002718.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2025111320453027000_12.1.e002718.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2025111320453027000_12.1.e002718.60","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"2025111320453027000_12.1.e002718.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007"},{"key":"2025111320453027000_12.1.e002718.62","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1126\/science.add2897","article-title":"T cell immunity to COVID-19 vaccines","volume":"377","author":"Wherry","year":"2022","journal-title":"Science"},{"key":"2025111320453027000_12.1.e002718.63","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.chom.2024.01.010","article-title":"Arming up against Omicron subvariants","volume":"32","author":"Altmann","year":"2024","journal-title":"Cell Host Microbe"},{"key":"2025111320453027000_12.1.e002718.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104684"},{"key":"2025111320453027000_12.1.e002718.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2211055"},{"key":"2025111320453027000_12.1.e002718.66","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh0761","article-title":"History of primary-series and booster vaccination and protection against Omicron reinfection","volume":"9","author":"Chemaitelly","year":"2023","journal-title":"Sci Adv"},{"key":"2025111320453027000_12.1.e002718.67","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13357","article-title":"BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar","volume":"18","author":"Chemaitelly","year":"2024","journal-title":"Influenza Other Respir Viruses"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:29:46Z","timestamp":1763393386000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,26]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjresp-2024-002718"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002718","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}